Novartis Zometa Data Supports Bone Metastases Use Across Tumor Types
Executive Summary
Novartis' Zometa data can be used to support a bone metastases indication across tumor types, FDA's Oncologic Drugs Advisory Committee agreed during a Jan. 31 meeting